Literature DB >> 19096012

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.

Bruno Chetaille1, François Bertucci, Pascal Finetti, Benjamin Esterni, Aspasia Stamatoullas, Jean Michel Picquenot, Marie Christine Copin, Frank Morschhauser, Olivier Casasnovas, Tony Petrella, Thierry Molina, Anne Vekhoff, Pierre Feugier, Reda Bouabdallah, Daniel Birnbaum, Daniel Olive, Luc Xerri.   

Abstract

The outcome of classical Hodgkin lymphoma (cHL) patients may be related to the tumor microenvironment, which in turn may be influenced by Epstein-Barr virus (EBV) infection. To characterize the cHL microenvironment, a set of 63 cHL tissue samples was profiled using DNA microarrays. Their gene expression profile differed from that of histiocyte T cell-rich B-cell lymphoma (H/TCRBCL) samples that were used as controls, mainly due to high expression of PDCD1/PD-1 in H/TCRBCL. EBV(+) cHL tissues could be distinguished from EBV(-) samples by a gene signature characteristic of Th1 and antiviral responses. Samples from cHL patients with favorable outcome overexpressed genes specific for B cells and genes involved in apoptotic pathways. An independent set of 146 cHL samples was analyzed using immunohistochemistry. It showed a significant adverse value in case of high percentage of either TIA-1(+)-reactive cells or topoisomerase-2(+) tumor cells, whereas high numbers of BCL11A(+), FOXP3(+), or CD20(+) reactive cells had a favorable influence. Our results suggest an antitumoral role for B cells in the cHL microenvironment and a stronger stromal influence of the PD1 pathway in H/TCRBCL than cHL. The observation of Th1/ antiviral response in EBV(+) cHL tissues provides a basis for novel treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19096012     DOI: 10.1182/blood-2008-07-168096

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  72 in total

1.  Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma.

Authors:  Beatriz Sánchez-Espiridión; Ana M Martin-Moreno; Carlos Montalbán; L Jeffrey Medeiros; Francisco Vega; Anas Younes; Miguel A Piris; Juan F Garcia
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 2.  Anti-CD30 Antibodies for Hodgkin lymphoma.

Authors:  Kelley V Foyil; Nancy L Bartlett
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

3.  Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma.

Authors:  Peter Kamper; Knud Bendix; Stephen Hamilton-Dutoit; Bent Honoré; Jens R Nyengaard; Francesco d'Amore
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

4.  Radiation exposure of the interventional radiologist during percutaneous biopsy using a multiaxis interventional C-arm CT system with 3D laser guidance: a phantom study.

Authors:  Nils Rathmann; Michael Kostrzewa; Kerim Kara; Soenke Bartling; Holger Haubenreisser; Stefan O Schoenberg; Steffen J Diehl
Journal:  Br J Radiol       Date:  2015-09-15       Impact factor: 3.039

5.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

Review 6.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

7.  T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Stefania Pittaluga; Elaine S Jaffe
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

8.  New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis.

Authors:  Kevin David Shield; Claire Marant Micallef; Catherine de Martel; Isabelle Heard; Francis Megraud; Martyn Plummer; Jérôme Vignat; Freddie Bray; Isabelle Soerjomataram
Journal:  Eur J Epidemiol       Date:  2017-12-06       Impact factor: 8.082

Review 9.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

Review 10.  How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

Authors:  Thomas S Uldrick; Richard F Little
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.